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INTRODUCTION
Renal dysfunction and myocardial and lung injury are
known to occur following cardiopulmonary bypass due
to systemic inflammatory response in patients
undergoing coronary artery bypass grafting (CABG).1-4
N-Acetyl-β-D-glucosaminidase (NAG) is a non-specific
marker of inflammation. The activity of this lysosomal
enzyme has been reported to be raised in a number of
inflammatory conditions, such as leukemia, rheumatoid
arthritis, chronic obstructive pulmonary disease and
acute myocardial infarction,5-8 indicating that its release
in inflammatory response along with other
proinflammatory cytokines could lead to end organ
damage.9 Attenuation of systemic inflammatory
response syndrome associated with a risk of increased
postoperative morbidity and mortality has been a
challenge in cardiac surgery.  Few studies have been
carried out to assess the role of NAG and other
proinflammatory cytokines as markers of postoperative
complications in patients undergoing CABG,10-13 and
none in Pakistan.
The present study was undertaken to determine the
changes in plasma NAG activity and levels of
proinflammatory cytokines, such as tumor necrosis
factor alpha (TNFα), interleukin 6 (IL-6) and interleukin
8 (IL-8) and granulocyte-macrophage colony stimulating
factor (GM-CSF). Immediately after and 5 days post
cardiac surgery with cardiopulmonary bypass.  Another
objective of this study was to find out the relationship of
plasma NAG activity and cytokines levels with clinical
outcome.
PATIENTS AND METHODS
Twelve consecutive patients, undergoing CABG at the
Aga Khan University Hospital, Karachi, between
January and June 2003, were included in this study.  All
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patients had either acute coronary syndrome or a non-
ST elevation myocardial infarction before surgery. None
had a recent major transmural myocardial infarction pre-
operatively. The study had been approved by the
Research Ethics Committee of the institution. Informed
consent was obtained from all the patients.
Three samples of blood were collected from each
patient at different time intervals. The first set of blood
samples was collected from a central venous catheter
placed at the time of surgery and collected before
systemic heparinization. Postoperatively, blood was
collected from the same central catheter after
administration of protamine. The samples were
transported to the laboratory immediately or following a
brief storage at 4°C. The day 5 samples were collected
from a peripheral vein prior to patient discharge.  Clinical
status of patients was monitored throughout their stay in
the hospital.
NAG activity was determined in plasma samples by the
method of Whiting et al.14 described in a previous
publication.8 One unit of NAG activity was defined as
that which released 1 µmole of 4-methylumbelliferone
per minute under assay conditions.  TNFα, IL-6, IL-8
and GM-CSF in plasma samples were analyzed using
the kits based on enzyme immunoassay by CHEMICON
International Inc (Temecula, CA, USA).
Mean values have been presented as means±standard
deviation (SD). Comparison of the two mean values at
two different time intervals was carried out by paired
sample t-test. One-way ANOVA followed by Tukey’s
HSD test was used for comparison of the distribution of
mean values of more than two groups. A p <0.05 was
considered significant.
RESULTS
Demographic and clinical characteristics of patients
have been listed in Table I. Mean values of NAG before,
immediately after and 5 days postprocedure were found
to be 5.7±1.6 U/l, 4.7±1.4 U/l and 7.3±1.4 U/l,
respectively. NAG activity before and immediately after
surgery were not significantly different indicating that
there was little change in NAG activity during surgical
procedure.  However, NAG activity 5 days post-CABG
was significantly increased (p=0.001).
Mean baseline NAG activity in diabetics was higher
compared to non-diabetics (Table II).  However, among
the non-diabetics, there was a significant increase in
plasma NAG activity (p=0.002) at day 5 post-CABG.
Among diabetics, there was an increase in mean NAG
activity on day 5 compared to baseline levels (7.95 ± 2.1
U/l vs. 6.92 ± 2 U/l), however, the increase was not
statistically significant (p=0.158).  
Plasma levels of cytokines, TNFα, IL-6, IL-8 and GM-
CSF before CABG, immediately after CABG and 5 days
post-CABG have been shown in Table III.  There was a
slight decrease immediately after CABG in the
concentration of three proinflammatory cytokines
(TNFα, IL-6 and IL-8).  However, 5 days post-CABG, the
levels of  IL-6 and IL-8 return to baseline levels, while
there is a significant increase in levels of TNF-α
(p=0.047).  Mean plasma levels of GM-CSF were found
to be significantly increased in samples obtained 5 days
post-CABG indicating boosted defense against
infections in these patients at this point in time.  There
was no relationship between NAG and the clinical
outcome.  Postoperative serum creatinine levels, mean
ventilatory time and heart function remained within
normal limits in all the patients. Radiologically, there was
no evidence of pneumonia in any of the study subjects.
Moreover, none of them had any clinical infection during
the postoperative period.
DISCUSSION
Cardiopulmonary bypass has been known to be one of
the major causes of systemic inflammatory response
after CABG and it may lead to multiple organ
dysfunctions.15 In a study by Hirai et al.,16 plasma levels
of proinflammatory cytokines IL-6 and IL-8 significantly
correlated with hepatic dysfunction and respiratory
dysfunction, respectively, in patients following CABG.
Wei et al.15 have demonstrated an association of
increased systemic proinflammatory cytokine levels with
postoperative myocardial dysfunction.
In pulmonary and renal damage, due to extracorporeal
perfusion, plasma NAG activity has been shown to be
significantly increased.1,3 The present results showed
no significant increase either in the plasma NAG activity
or in the plasma levels of TNFα, IL-6, IL-8 or GM-CSF
immediately after the surgical procedure. However,
there was a significant increase in plasma NAG activity
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Table I:  Demographic and clinical characteristics of patients 
undergoing coronary artery bypass grafting (CABG).
Variable Means ± SD Frequency (%)
Age (years) 52.8 ± 9.5 -
Gender
Male - 10(83.3) 
Female - 2(16.7)
BMI (kg/m2) 26.5 ± 4.1 -
Diabetes
Yes - 4(33.3)
No - 8(67.7)
Hypertension
Yes - 10(83.3)
No - 2(16.7)
Angina duration (days) 3.5 ± 2.6 -
Time on CPB (min) 124 ± 26 -
Cross-clamp time (min) 74 ± 17 -
Serum creatinine (mg/dl) 0.98 ± 0.17 -
at day 5 post-CABG. Though speculative at this
moment, these findings suggest that cardiopulmonary
bypass causes a systemic inflammatory response that
might be responsible for organ damage within 5 days
following surgical procedure. TNF-α appears to be the
major inflammatory cytokine produced by day 5
following surgery and its level was found to be increased
along with that of NAG. It is clinically important to
attenuate the inflammation that takes place during
cardiopulmonary bypass and the inflammation of
myocardium after ischemia and following re-perfusion,
since these affect the clinical status of patients after
cardiopulmonary bypass as well as myocardial
functions. Different agents such as diltiazem,17
cimetidine18 and corticosteroids3 have been used to
inhibit systemic inflammatory response to surgery.  Off-
pump coronary re-vascularization is another approach
adopted to minimize physiological insult associated with
CABG.19
Though NAG and TNF-α were found to be significantly
increased on day 5 in patients undergoing CABG in this
study, they did not affect the clinical outcome and, renal,
pulmonary and cardiac function parameters remained
within normal limits suggesting that anti-inflammatory
processes neutralized any deleterious effects of the
inflammatory cytokines.
GM-CSF is often considered to be responsible for host’s
defense against infections as it has been shown to
increase neutrophil count as well as enhance the
cytotoxic activity of macrophages and natural killer
cells.20 Therefore, an increase on day 5 following
CABG (Table III) shows enhanced body’s defense
mechanism against infection.  These results conform
well to those reported by Hirai et al.16 who have also
shown increased plasma levels of macrophage colony
stimulating factor 48 hours post-cardiopulmonary
bypass. This result (elevated levels of GM-CSF on day
5 post-CABG) is significant as most of the work done to-
date has been on other cytokines associated with
systemic inflammatory response following
cardiopulmonary bypass.  Elevation of the profile of GM-
CSF as observed in this study is important as it will help
us understand how body balances the proinflammatory
processes and the defence against infection following
cardiopulmonary bypass.  
The mean plasma NAG activity values in acute
myocardial infarction (AMI) patients and normal healthy
subjects are 10.92 ± 7.5 U/l and 6.8 ± 2.2 U/l,
respectively.8 In the present study, the mean baseline
plasma NAG activity in angina patients undergoing
CABG has been found to be 5.73 ± 1.6 U/l, which is not
significantly different from the NAG activity in normal
healthy subjects.  This lends support to the initial
hypothesis that AMI is an acute inflammatory condition
and NAG activity in plasma would be expected to be
elevated in it.  However, angina patients would only
exhibit elevated NAG activity following induction of pro-
inflammatory cytokines, especially TNFα. Similarly,
enhanced baseline levels of NAG in diabetics compared
to non-diabetics (Table II) is in line with the hypothesis
that diabetes mellitus is an inflammatory disease,21
therefore, a marker of inflammation, such as NAG would
be expected to be increased in this disease. The
enhanced inflammatory response on day 5 might be
responsible for some organ damage resulting in a
further increase in plasma NAG activity.  However, a
simultaneous increase in plasma GM-CSF level at the
same time post-CABG appears to suggest increased
defense mechanism against infection.  
A relatively small sample size of patients (n=12) may be
considered as a limitation of this study.  However, it is
not uncommon to find in the international literature pilot
level studies pertaining to changes in cytokines in
cardiopulmonary bypass using a small number of
patients.  For example, Gormley et al. have monitored
changes in cytokine levels in 8 patients undergoing
cardiac surgery,10 while Hirai et al. studied such changes
in 11 patients.16
This data suggest that NAG can be a potential marker
for inflammation and possibly for organ damage
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Table II:  Serum glucose levels and plasma NAG activity in diabetic and non-diabetic angina patients before, immediately after and 5 days
post-coronary artery bypass grafting (CABG). (means +SD) 
Patients No. Glucose concentration (mg/dl) *P NAG activity (U/l) **P
(n) Before Immediately 5 days Before Immediately 5 days
CABG after CABG Post CABG CABG after CABG Post CABG
Diabetic 4 218 ± 66 210 ± 37 214 ± 25 0.61 6.92 ± 2 5.35 ± 0.54 7.95 ± 2.1 0.158
Non-diabetic 8 82 ± 21 153 ± 59 118 ± 35 0.012 5.14±0.99 4.36 ± 1.56 6.98 ± 0.96 0.002
*P compares mean glucose concentration before CABG with mean glucose concentration immediately after CABG by paired samples t-test.
**P compares all 3 means values of NAG activity (before, immediately after and 5 days postprocedure) in the row using one-way ANOVA.
Table III: Plasma levels of cytokines in angina patients before,
immediately after and 5 days post
coronary artery grafting
(CABG) (means ± SD).
Plasma concentration (ng/ml)
Cytokine Before CABG Immediately 5 Days post- *P
after CABG CABG
TNF-α 1.43 ± 1 1.06 ± 0.62 2.5 ± 2.12** 0.047
IL-6 1.22± 1.66 1.2 ± 1.28 1.2 ± 1.28 0.454
IL-8 0.48 ± 0.44 0.41 ± 0.27 0.58 ± 0.56 0.81
GM-CSF 0.01 ± 0.011 0.011 ± 0.006 0.033 ± 0.038** 0.045
*P compares the 3 mean values of each cytokine by one-way ANOVA followed by 
Tukey’s HSD test.
following CABG using cardiopulmonary bypass.
However, further studies using a large number of
patients would be required to ascertain its role as a
predictor of end-organ damage.  Strategies to attenuate
this proinflammatory response, such as, anti-TNF
therapy22, off-pump CABG19, and increasing plasma
GM-CSF level to boost body’s defences20, could play a
role in reducing mortality and morbidity associated with
cardiac surgery. 
CONCLUSION
Increased levels of NAG and TNFα did not affect clinical
outcome in patients undergoing cardiac surgery.
However, the data suggest that NAG can be a potential
marker for inflammation and end organ damage
following CABG.  An increase in GM-CSF on day 5
following CABG indicates enhanced body’s defense
mechanism against infection. Strategies to boost the
body’s defenses by increasing plasma GM-CSF level
could be important in reducing mortality and morbidity
associated with CABG.
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